Ob/Gyn Medical News about Testosterone

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Testosterone supplementation: For whom and when?
Sexuality, Reproduction & Menopause, 10/08/09

Khera M – Evidence shows that testosterone, added to estrogen therapy (ET), improves sexual function in women and may improve bone health. However, the absence of an FDA–approved agent, off–label use raises questions about patient selection, dosing, and safety. Approval of testosterone–containing preparations has been deferred pending confirmation of long–term safety assessments (2–5 years). Evidence suggests that testosterone supplementation does not increase the risk of breast cancer; it may have a protective effect on breast tissue. A longer time to disease progression and a higher response rate is observed when androgens are added to anti–estrogen therapy. Long–term androgen administration does not have significant, adverse effects on female breast tissue. Nevertheless, testosterone can still be aromatized to estrogen; patients with a history of estrogen–sensitive breast cancer should be discouraged from treatment. No convincing data suggest that testosterone use increases the risk of cardiovascular events in women. Although oral methyltestosterone has been shown to reduce HDL and raise LDL levels in women, this effect is not seen in association with other forms of testosterone. Finally, no evidence indicates that testosterone supplementation increases the risk of endometrial cancer.

<< Previous
Association between prepregnancy body mass index and congenital...

Next >>
Immunologic factors and reproductive success in women with...

Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09 Relevance Score: 95%

Testosterone and biological characteristics of breast cancers in postmenopausal women
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09 Relevance Score: 94%

Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets
European Journal of Endocrinology, 11/17/09 Relevance Score: 91%

NIH-Supported Trial to Study Testosterone Therapy in Older Men
MedLinePlus, 11/04/09 Relevance Score: 91%

NIH-Supported Trial to Study Testosterone Therapy in Older Men
NIH, 11/03/09 Relevance Score: 91%